Search results
Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012
Zacks via Yahoo Finance· 1 year agoThe FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline...
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 2 years agoKala Pharma (KALA) delivered earnings and revenue surprises of 13.64% and 18.13%, respectively, for...
Kala Pharmaceuticals (KALA) Gains As Market Dips: What You Should Know
Zacks via Yahoo Finance· 1 year agoKala Pharmaceuticals (KALA) closed the most recent trading day at $12.99, moving +1.64% from the...
KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus
Zacks via Yahoo Finance· 1 year agoKala Pharmaceuticals KALA reported a fourth-quarter 2022 loss of $7.97 per share, narrower than the...
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
Investor's Business Daily· 1 year agoKala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 67 to 83 Friday. When...
Kala Pharma (KALA) Moves to Buy: Rationale Behind the Upgrade
Zacks via Yahoo Finance· 2 years agoKala Pharmaceuticals (KALA) appears an attractive pick, as it has been recently upgraded to a Zacks...
KALA Up on Fast Track Designation to Lead Ocular Candidate
Zacks via Yahoo Finance· 1 year agoKala Pharmaceuticals, Inc. KALA, a clinical-stage biopharmaceutical company’s shares were up 2.52%...
Kala Pharmaceuticals (KALA) Recently Broke Out Above the 200-Day Moving Average
Zacks via Yahoo Finance· 1 year agoKala Pharmaceuticals (KALA) reached a significant support level, and could be a good pick for...
Kala Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 2 years agoKala Pharmaceuticals (NASDAQ:KALA) Third Quarter 2022 ResultsKey Financial Results Net income:...
Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus...
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – March 22, 2023 – Today, Zacks Equity Research discusses CRISPR...